Anti-Rheumatic Drugs - Ukraine | Statista Market Forecast

In Ukraine, the revenue in the Anti-Rheumatic Drugs market is estimated to reach US$14.80m in 2024.
It is projected to experience a steady annual growth rate (CAGR 2024-2029) of 0.96%, leading to a market volume of US$15.52m by 2029.
When comparing globally, United States is expected to generate the highest revenue in this market, with US$34.70bn in 2024.
In Ukraine, there is a growing demand for innovative anti-rheumatic drugs due to the increasing prevalence of rheumatic diseases.

Definition:
The market Anti-Rheumatic Drugs includes medication for the treatment of the inflammatory disease rheumatism. Due to the high prevalence of rheumatism and the large size of the market, this section of immune diseases is treated as a separate market. Both steroidal and non-steroidal anti-rheumatics are included. Disease-modifying rheumatic drugs (DMARDs), such as tumor necrosis factor inhibitors (a type of biologic DMARD), are particularly important in terms of commerciality.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: AbbVie, Johnson & Johnson, Pfizer, Amgen, Roche

Drugs to treat rheumatism
Steroidal (corticosteroids) and non-steroidal anti-rheumatics
Disease-modifying antirheumatic drugs (DMARDs)
Tumor necrosis factor (TNF) inhibitors

Drugs to treat other autoimmune diseases (such as multiple sclerosis or psoriasis)
Analgetics for general use (such as paracetamol)
Treatment of osteoarthritis

The Anti-Rheumatic Drugs market in Ukraine has been steadily growing over the past few years, with a significant increase in demand for these drugs.

Customer preferences: Patients in Ukraine suffering from rheumatoid arthritis and other related diseases have been increasingly turning to Anti-Rheumatic Drugs for relief. This is due to the fact that these drugs are highly effective in treating the symptoms of these diseases, including inflammation, pain, and stiffness.

Trends in the market: One of the main trends in the Anti-Rheumatic Drugs market in Ukraine is the increasing availability of these drugs. This is due to the fact that many pharmaceutical companies have recognized the growing demand for these drugs and have begun to invest more heavily in their production and distribution. As a result, patients in Ukraine now have access to a wider range of Anti-Rheumatic Drugs than ever before.Another trend in the market is the increasing use of biologic drugs. These drugs are highly effective in treating rheumatoid arthritis and other related diseases, and are becoming increasingly popular among patients in Ukraine. This is due to the fact that biologic drugs have fewer side effects than traditional medications, and are often more effective in treating the underlying causes of these diseases.

Local special circumstances: One of the main factors driving the growth of the Anti-Rheumatic Drugs market in Ukraine is the high prevalence of rheumatoid arthritis and other related diseases in the country. According to recent studies, Ukraine has one of the highest rates of rheumatoid arthritis in the world, with over 1 million people suffering from the disease.

Underlying macroeconomic factors: Another factor driving the growth of the Anti-Rheumatic Drugs market in Ukraine is the improving economic conditions in the country. As the economy continues to recover from the crisis of the past few years, more people are able to afford these drugs and are seeking out treatment for their rheumatoid arthritis and other related diseases.Overall, the Anti-Rheumatic Drugs market in Ukraine is expected to continue growing in the coming years, driven by increasing demand for these drugs and improving economic conditions in the country. As pharmaceutical companies continue to invest in the production and distribution of these drugs, patients in Ukraine will have access to a wider range of effective treatments for their rheumatoid arthritis and other related diseases.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.